Arcturus Therapeutics

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics
image_banner
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://arcturusrx.com/wp-content/uploads/2023/01/JoePayne_LanguageProficiency_V3_1.mp4
arabic
(عربى)
https://arcturusrx.com/wp-content/uploads/2023/01/MaherA_LanguageProficiency_V3_1.mp4
chinese
(中文)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_BelleBao.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/BelleBao_LanguageProficiency__V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_HowardYu.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/HowardYu_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_YurongGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/YurongGuo_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_XuefengGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/XuefengGuo_LanguageProficiency_V3_1.mp4
english
(British)
https://arcturusrx.com/wp-content/uploads/2023/01/MikeHodges_LanguageProficiency_V3_1.mp4
farsi
(فارسی)
https://arcturusrx.com/wp-content/uploads/2023/01/NedaSafarzadeh_LanguageProficiency_V5.mp4
french
(Français)
https://arcturusrx.com/wp-content/uploads/2023/01/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4
german
(deutsch)
https://arcturusrx.com/wp-content/uploads/2023/01/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4
hebrew
(עִברִית)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_NoaScott.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/NoaScott_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_TamarGrossman.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/TamarGrossman_LanguageProficiency_V3_1.mp4
hindi
(हिन्दी)
https://arcturusrx.com/wp-content/uploads/2023/01/PriyaKarmali_LanguageProficiency_V3_1.mp4
italian
(italiano)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_CristianoSacchetti.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/CristianoSacchetti_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_GiulioCattarossi.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/GiulioCattarossi_LanguageProficiency_V3_1.mp4
Japanese
(日本語)
https://arcturusrx.com/wp-content/uploads/2023/01/Kiyoshi_Tachikawa_v2.mp4
korean
(한국어)
https://arcturusrx.com/wp-content/uploads/2023/01/JaeHeonKim_LanguageProficiency_V3_1.mp4
portuguese
(Português)
https://arcturusrx.com/wp-content/uploads/2023/01/RamonDiazTrelles_LanguageProficiency_V3_1.mp4
spanish
(español)
https://arcturusrx.com/wp-content/uploads/2023/01/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4
vietnamese
(Tiếng Việt)
https://arcturusrx.com/wp-content/uploads/2023/01/HannahHuynh_LanguageProficiency_V3_1.mp4

News & Events

February 22, 2024
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
February 20, 2024
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
February 5, 2024
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
December 21, 2023
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
December 4, 2023
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
November 28, 2023
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
November 27, 2023
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
November 14, 2023
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
October 25, 2023
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
October 23, 2023
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
October 4, 2023
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
September 26, 2023
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
September 19, 2023
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
September 5, 2023
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
August 17, 2023
Arcturus Therapeutics to Attend Upcoming Investor Conferences
August 14, 2023
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
August 7, 2023
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
July 24, 2023
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
June 1, 2023
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
May 9, 2023
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress

LUNAR® Mechanism of Delivery